CHAMPIONS ONCOLOGY, INC. financial data

Symbol
CSBR on Nasdaq
Location
Baltimore, MD
Fiscal year end
30 April
Latest financial report
10-Q - Q4 2025 - 12 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 95% % 25%
Debt-to-equity 671% % -74%
Return On Equity -57% % -109%
Return On Assets -7.5% % -131%
Operating Margin -4.5% % -142%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13,886,826 shares 0.43%
Common Stock, Shares, Outstanding 13,886,826 shares 1.3%
Entity Public Float $15,400,000 USD -30%
Common Stock, Value, Issued $14,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 13,886,797 shares 1.4%
Weighted Average Number of Shares Outstanding, Diluted 13,886,797 shares -3.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $57,944,000 USD -1.1%
Research and Development Expense $8,932,000 USD 29%
Selling and Marketing Expense $8,828,000 USD 26%
General and Administrative Expense $11,044,000 USD 15%
Operating Income (Loss) $2,625,000 USD -142%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $2,399,000 USD -137%
Income Tax Expense (Benefit) $56,000 USD -107%
Net Income (Loss) Attributable to Parent $2,282,000 USD -136%
Earnings Per Share, Basic -0.17 USD/shares -136%
Earnings Per Share, Diluted -0.15 USD/shares -134%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $7,127,000 USD 123%
Accounts Receivable, after Allowance for Credit Loss, Current $12,067,000 USD -24%
Assets, Current $20,185,000 USD 2.5%
Operating Lease, Right-of-Use Asset $4,026,000 USD -25%
Goodwill $335,000 USD 0%
Other Assets, Noncurrent $196,000 USD 5.9%
Assets $28,447,000 USD -7.1%
Accounts Payable, Current $5,726,000 USD 12%
Accrued Liabilities, Current $3,346,000 USD 48%
Contract with Customer, Liability, Current $9,998,000 USD -8.5%
Liabilities, Current $20,677,000 USD 4.1%
Operating Lease, Liability, Noncurrent $3,365,000 USD -33%
Other Liabilities, Noncurrent $27,000 USD -91%
Liabilities $24,069,000 USD -4.3%
Retained Earnings (Accumulated Deficit) $80,400,000 USD -3%
Stockholders' Equity Attributable to Parent $4,283,000 USD -22%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $4,378,000 USD -20%
Liabilities and Equity $28,447,000 USD -7.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $600,000 USD 93%
Net Cash Provided by (Used in) Financing Activities $14,000 USD 62%
Net Cash Provided by (Used in) Investing Activities $46,000 USD
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 14,007,159 shares 1.3%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $540,000 USD 97%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7,127,000 USD 123%
Deferred Tax Assets, Valuation Allowance $14,838,000 USD -18%
Deferred Tax Assets, Gross $14,838,000 USD -18%
Operating Lease, Liability $4,894,000 USD -24%
Payments to Acquire Property, Plant, and Equipment $46,000 USD
Lessee, Operating Lease, Liability, to be Paid $8,791,000 USD -26%
Property, Plant and Equipment, Gross $16,181,000 USD -3%
Operating Lease, Liability, Current $1,529,000 USD 6.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,816,000 USD -3.4%
Lessee, Operating Lease, Liability, to be Paid, Year One $2,869,000 USD -2.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.0582 pure -1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $3,897,000 USD -28%
Lessee, Operating Lease, Liability, to be Paid, Year Three $2,364,000 USD -18%
Deferred Tax Assets, Operating Loss Carryforwards $8,248,000 USD -8.7%
Unrecognized Tax Benefits $0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Four $2,392,000 USD -17%
Depreciation, Depletion and Amortization $1,410,000 USD -19%
Share-based Payment Arrangement, Expense $1,011,000 USD 29%